Hoshino Shota, Takeuchi Masashi, Kawakubo Hirofumi, Matsuda Satoru, Mayanagi Shuhei, Irino Tomoyuki, Fukuda Kazumasa, Nakamura Rieko, Wada Norihito, Kitagawa Yuko
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Ann Surg Oncol. 2021 Jun;28(6):3001-3008. doi: 10.1245/s10434-021-09637-0. Epub 2021 Mar 10.
Although radical esophagectomy with multifield lymph node dissection is a promising treatment to achieve long-term survival for resectable esophageal cancer, survival after postoperative recurrence remains poor. To select the optimal treatment for patients with recurrent esophageal cancer, simple, objective indicators for predicting of long-term outcomes are needed.
We conducted a single-institution, retrospective cohort study between 2004 and 2019, wherein 586 patients underwent transthoracic esophagectomy for primary esophageal squamous cell carcinoma. Of these, 133 patients with postoperative recurrence were included in this analysis. Several predictors of survival after recurrence were investigated.
Among all patients, the 1- and 3-year survival rates after recurrence were 48.0% and 23.1%, respectively. On multivariate analysis, the neutrophil to lymphocyte ratio (NLR) at recurrence was identified as a significant predictor of death after recurrence (hazard ratio 1.061; 95% confidence interval 1.002-1.125; p = 0.043). Time-dependent receiver operating characteristics curves showed that the area under the curve value of the NLR at recurrence was superior to the modified Glasgow Prognostic Score at recurrence in all terms. To simulate the clinical decision process, we set the cut-off NLR at recurrence for survival using survival classification and regression tree (CART) and defined the optimal cut-off value as 3.374.
NLR at recurrence was a significant indicator of survival after recurrence in patients with recurrent esophageal cancer. CART analysis was used to determine the optimal cut-off value for the prediction of survival, allowing the NLR to be used clinically to facilitate decision making.
尽管根治性食管切除术联合多野淋巴结清扫术是有望实现可切除食管癌长期生存的一种治疗方法,但术后复发后的生存率仍然很低。为了为复发性食管癌患者选择最佳治疗方案,需要简单、客观的指标来预测长期预后。
我们在2004年至2019年期间进行了一项单机构回顾性队列研究,其中586例患者因原发性食管鳞状细胞癌接受了经胸食管切除术。其中,133例术后复发患者纳入本分析。研究了复发后生存的几个预测因素。
在所有患者中,复发后的1年和3年生存率分别为48.0%和23.1%。多因素分析显示,复发时的中性粒细胞与淋巴细胞比值(NLR)是复发后死亡的重要预测因素(风险比1.061;95%置信区间1.002-1.125;p=0.043)。时间依赖性受试者工作特征曲线显示,复发时NLR的曲线下面积值在各方面均优于复发时的改良格拉斯哥预后评分。为了模拟临床决策过程,我们使用生存分类与回归树(CART)设定复发时用于生存的NLR临界值,并将最佳临界值定义为3.374。
复发时的NLR是复发性食管癌患者复发后生存的重要指标。CART分析用于确定预测生存的最佳临界值,使NLR能够在临床上用于辅助决策。